Compare Fresenius Kabi Onco. with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs GLENMARK PHARMA - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. GLENMARK PHARMA FRESENIUS KABI ONCO./
GLENMARK PHARMA
 
P/E (TTM) x 22.1 10.6 208.6% View Chart
P/BV x 3.1 1.5 205.3% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 FRESENIUS KABI ONCO.   GLENMARK PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
GLENMARK PHARMA
Mar-19
FRESENIUS KABI ONCO./
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs176712 24.7%   
Low Rs79484 16.2%   
Sales per share (Unadj.) Rs37.7349.6 10.8%  
Earnings per share (Unadj.) Rs5.132.8 15.5%  
Cash flow per share (Unadj.) Rs6.744.3 15.2%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs42.5198.6 21.4%  
Shares outstanding (eoy) m158.23282.17 56.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.7 197.6%   
Avg P/E ratio x25.018.2 137.1%  
P/CF ratio (eoy) x18.913.5 140.4%  
Price / Book Value ratio x3.03.0 99.4%  
Dividend payout %06.1 0.0%   
Avg Mkt Cap Rs m20,135168,625 11.9%   
No. of employees `0001.212.0 9.6%   
Total wages/salary Rs m70320,561 3.4%   
Avg. sales/employee Rs Th5,176.28,196.0 63.2%   
Avg. wages/employee Rs Th610.41,708.1 35.7%   
Avg. net profit/employee Rs Th699.6768.5 91.0%   
INCOME DATA
Net Sales Rs m5,96398,655 6.0%  
Other income Rs m182,081 0.9%   
Total revenues Rs m5,981100,736 5.9%   
Gross profit Rs m1,43015,858 9.0%  
Depreciation Rs m2583,259 7.9%   
Interest Rs m-263,346 -0.8%   
Profit before tax Rs m1,21611,335 10.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-681,672 -4.1%   
Tax Rs m3423,756 9.1%   
Profit after tax Rs m8069,250 8.7%  
Gross profit margin %24.016.1 149.2%  
Effective tax rate %28.133.1 84.9%   
Net profit margin %13.59.4 144.1%  
BALANCE SHEET DATA
Current assets Rs m5,10266,968 7.6%   
Current liabilities Rs m2,38540,211 5.9%   
Net working cap to sales %45.627.1 167.9%  
Current ratio x2.11.7 128.4%  
Inventory Days Days15083 180.1%  
Debtors Days Days11381 139.5%  
Net fixed assets Rs m5,14833,322 15.4%   
Share capital Rs m158282 56.1%   
"Free" reserves Rs m6,55655,770 11.8%   
Net worth Rs m6,73256,052 12.0%   
Long term debt Rs m95235,738 2.7%   
Total assets Rs m10,388132,888 7.8%  
Interest coverage x-45.84.4 -1,043.3%   
Debt to equity ratio x0.10.6 22.2%  
Sales to assets ratio x0.60.7 77.3%   
Return on assets %7.59.5 79.2%  
Return on equity %12.016.5 72.5%  
Return on capital %14.617.8 82.0%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29862,998 8.4%   
Fx outflow Rs m1,77222,859 7.8%   
Net fx Rs m3,52540,140 8.8%   
CASH FLOW
From Operations Rs m1,27413,242 9.6%  
From Investments Rs m-1,204-6,990 17.2%  
From Financial Activity Rs m-196-7,387 2.7%  
Net Cashflow Rs m-126-2,971 4.3%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 6.9 4.3%  
FIIs % 9.6 34.4 27.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.5 86.7%  
Shareholders   42,599 56,727 75.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   GSK PHARMA  ASTRAZENECA PHARMA  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS